Huayi Li

5PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCoding, information theory and compression
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 10, 2026
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.

|Feb 13, 2023
Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.

Ping Jin, Xin Li, Yu Xia

|Jun 10, 2021
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.

Xiaoting Li, Tian Fang, Sen Xu

|May 09, 2021
C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.

Jiahong Tan, Xu Zheng, Mengchen Li

|Oct 07, 2020
Machine learning based early warning system enables accurate mortality risk prediction for COVID-19.

Yue Gao, Guang-Yao Cai, Wei Fang

Pageof 1

Frequent Collaborators

4 joint publications

Qinglei Gao

2 joint publications

Fei Ye

1 joint publications

Peng-Fei Cui

1 joint publications

Jiahong Tan